Jennie W. Taylor

This study identifies IL-6 as a driver of immunosuppression in glioblastoma, showing that its inhibition enhances response to immune checkpoint therapy and radiotherapy in preclinical models.

This study identifies PHGDH-driven D-2HG production as a mechanism of resistance to vorasidenib in IDHm gliomas and introduces deuterium metabolic imaging as a non-invasive method to detect resistance.